Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07176390 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
A Phase 2 study of Arthritis, Rheumatoid, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT07176390: Recruiting Phase 2 study of Arthritis, Rheumatoid, sponsored by Merck Sharp & Dohme.
NCT07176390 is a Phase 2 study of Arthritis, Rheumatoid that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 182 participants, below the 634-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07176390, a Phase 2 study of Arthritis, Rheumatoid, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Primary Outcome
The ACR20 response is a composite measure to evaluate disease activity in RA. ACR20 response is defined as a ≥20% improvement in: a) swollen joint count (66 joints) and tender joint count (68 joints) (0= Absent; 1= Present) and b) ≥20% improvement in ≥3 of the following 5 assessments and questionnaires: i) Health Assessment Questionnaire Disability Index (HAQ-DI) (0=without any difficulty; 3= unable to do) a higher score=worse disability, ii) Physician Global Assessment of Disease Activity (PGA)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG Tulisokibart
Study Locations (20)
Texas
- Rheumatology Associates ( Site 1026) - Arlington
- Epic Medical Research ( Site 1004) - Red Oak
- Advanced Rheumatology of Houston - Woodlands ( Site 1000) - The Woodlands
Arizona
- Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018) - Glendale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033) - Mesa
Florida
- Sweet Hope Research Specialty, Inc ( Site 1015) - Hialeah
- HMD Research LLC ( Site 1016) - Orlando
Pennsylvania
- altoona center for clinical research ( Site 1005) - Duncansville
- Rheumatology Specialty Center ( Site 1030) - Willow Grove
Quebec
- CIUSSS de l'Estrie - CHUS, Hotel-Dieu de Sherbrooke ( Site 1106) - Sherbrooke
- Centre de Recherche Musculo-Squelettique ( Site 1101) - Trois-Rivières
Region M. de Santiago
- Centro de Estudios GyC ( Site 1206) - Santiago
- Clinica Dermacross ( Site 1203) - Santiago
California
- Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024) - La Palma
Colorado
- Tekton Research, LLC. ( Site 1008) - Fort Collins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2029-09-03 |
| Phase | Phase 2 |
What NCT07176390 shows while recruiting
NCT07176390 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07176390 names 20 study sites across 13 states, led by Texas, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07176390 about?
NCT07176390 is a clinical study titled "A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)". Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart...
What is the current status of trial NCT07176390?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2025-10-08. Estimated completion is 2029-09-03.
What conditions does trial NCT07176390 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT07176390?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), Tulisokibart (DRUG).
Who is sponsoring clinical trial NCT07176390?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07176390 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07176390's enrollment target sits among peer trials
182 18th of 27 higher than 10 of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
COMPLETED · Phase 2
-
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
COMPLETED · Phase 2
-
Low Dose Naltrexone for Chronic Pain From Arthritis
COMPLETED · Phase 2
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI